NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update Jun 1, 2026 08:02AM
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology May 19, 2026 04:04PM
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production Apr 27, 2026 04:03PM
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update Apr 16, 2026 09:15AM
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026 Apr 10, 2026 04:03PM


Feb 27, 2026 04:03PM NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
Feb 10, 2026 04:03PM NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Dec 19, 2025 04:04PM NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
Nov 12, 2025 04:02PM NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
Nov 3, 2025 04:04PM NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
Sep 8, 2025 04:30PM NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
Aug 20, 2025 04:03PM NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
Jul 25, 2025 04:02PM NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
May 8, 2025 04:04PM NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 2, 2025 04:05PM NurExone Expands European Engagement with Investor Events in Germany and Switzerland
Mar 10, 2025 09:00AM NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
Jan 21, 2025 04:20PM NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
Dec 3, 2024 07:00AM Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
Oct 31, 2024 07:00AM NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule
Oct 30, 2024 07:00AM Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
Oct 29, 2024 07:00AM Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
Aug 28, 2024 08:34AM NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 9, 2024 04:04PM NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
Jul 17, 2024 07:00AM Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Jun 21, 2024 04:04PM On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Jun 4, 2024 04:40PM NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
May 29, 2024 08:35AM NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
May 17, 2024 04:04PM NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations